[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
Last updated December 3, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

703.O2.6 Tumor Immunotherapy: Clinical Cellular Immunotherapies

Oral and Poster Abstracts
Oral Session
Monday, December 7, 2009: 4:30 PM-6:00 PM
388-390 (Ernest N. Morial Convention Center)
Moderators:
Richard J. O'Reilly, MD and Donna E. Hogge, MD, PhD
4:30 PM
CT-011, Anti-PD-1 Antibody, Enhances Ex-Vivo T Cell Responses to Autologous Dendritic/Myeloma Fusion Vaccine Developed for the Treatment of Multiple Myeloma

Jacalyn Rosenblatt, M.D.1, Brett Glotzbecker, MD1*, Heidi Mills1*, Whitney Keefe1*, Kerry Wellenstein1*, Baldev Vasir, PhD2*, Zekui Wu, MD2*, Corrine Zarwan, MD1*, Michael Schickler, PhD3*, Rinat Rotem-Yehudar, PhD3*, Donald Kufe, MD2* and David Avigan, MD1

1Beth Israel Deaconess Medical Center, Boston, MA
2Dana Farber Cancer Institute, Boston, MA
3CureTech Ltd., Israel

4:45 PM
Establishing CD8+ T Cell Immunity by Adoptive Transfer of Autologous, IL-15 Expanded, Anti-Tumor CTL with a Central/Effector Memory Phenotype Can Induce Objective Clinical Responses

Marcus Butler*, Philip Friedlander*, Mary Mooney*, Linda Drury*, Martha Metzler*, Matthew Milstein*, Alla Berezovskaya*, Marisa Flavin*, Osamu Imataki, Makito Tanaka, Heather Daley*, F. Stephen Hodi*, Lee Nadler and Naoto Hirano

Dana-Farber Cancer Institute, Boston, MA

5:00 PM
Dendritic Cell Tumor Fusion Vaccination in Conjunction with Autologous Transplantation for Multiple MyelomaClinically Relevant Abstract

Jacalyn Rosenblatt, MD1, Irit Avivi, MD2*, Baldev Vasir, PhD3*, Tami Katz, Ph.D2*, Lynne Uhl, MD1*, Zekui Wu, MD3*, Poorvi Somaiya1*, Heidi Mills1*, Robin Joyce, MD1, James D. Levine, MD1, Dimitrios Tzachanis, MD, PhD1, Vassiliki Boussiotis, MD, PhD1*, Brett Glotzbecker, MD1, Karen Francoeur1*, Dilani Dombagoda1*, Michal Tsumer2*, Lina Bisharat2*, Nancy Giallombardo, NP1*, Katharine Conway, NP1*, Donna Fitzgerald, PA1*, Rachal Barhad2*, Paul Richardson, M.D., Ph.D.3, Kenneth C. Anderson, M.D., Ph.D.3, Nikhil C. Munshi, MD3, Jacob M. Rowe, MD2, Donald Kufe, MD3* and David Avigan, MD1

1Beth Israel Deaconess Medical Center, Boston, MA
2Rambam Medical Center, Haifa 31096, Israel
3Dana-Farber Cancer Institute, Boston, MA

5:15 PM
Schedule Dependent Effects of Adoptively Transferred Autologous T Cells After AutoSCT for Myeloma:  Accelerated Immune Recovery Is Associated with Improved Event-Free SurvivalClinically Relevant Abstract

Aaron P. Rapoport, MD1, Nicole A. Aqui, MD2, Edward A. Stadtmauer, MD3, Dan T. Vogl, MD3, Hong-Bin Fang, PhD1*, Stephen Janofsky, BS2*, Jan Storek, MD, PhD4*, Anne Chew, PhD3*, Elizabeth Veloso, JD3*, Gorgun Akpek, MD, MS1, Saul Yanovich, MD1, Ming T. Tan, PhD1*, Yin Wu, MD1*, Alan Cross, MD1*, Sunita Philip, MPH1*, Heather Murphy3*, Rita Bhagat, RN3*, Yiping Liu4*, Bruce Levine, PhD3*, Robert H. Vonderheide, MD, DPhil3* and Carl H. June, MD3

1University of Maryland, Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD
2Dept. of Pathology, Univ. of Pennsylvania, Philadelphia, PA
3Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA
4The University of Calgary, Calgary, AB, Canada

5:30 PM
High Doses of Moternal Lymphocyte Infusions to Treat EBV-Associated Lymphoma in Pediatric PatientsClinically Relevant Abstract

Qian Wang* and Ping Zhu, MD

Dept.of Hematology, Peking University First Hospital, Beijing, China

5:45 PM
Adoptive Transfer of Natural Killer (NK) Cells to Prevent Gvhd and Enhance GVT Effects After Allogeneic Hematopoietic Cell Transplantation (HCT): The Timing of Donor NK Cell Infusions Critically Impacts Transplant Outcome

Andreas Lundqvist1*, Hisayuki Yokoyama, MD, PhD2 and Richard W. Childs, MD3

1Nhlbi, NIH, Hematology Branch, Bethesda, MD
2Hematology Branch, NHLBI, NIH, Bethesda, MD
3Nhlbi, NIH, National, Heart, Lung & Blood Institute, National Institutes of Health, Bethesda, MD

*signifies non-member of ASH